You are here

Urge Incontinence Treatment Approved for Marketing in the European Union

CORONA, Calif., June 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the European Union's Commission of the European Communities has granted marketing authorization to Watson's oxybutynin transdermal product for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with unstable bladder.

Approval of the application, filed by Watson's wholly-owned European subsidiary, results in a single Marketing Authorization with unified labeling that is immediately valid in all 25 EU-Member States.

On September 24, 2003, Watson announced that it had entered into a marketing and supply agreement with UCB Pharma, pursuant to which UCB Pharma will market the oxybutynin transdermal product in Europe. UCB Pharma expects to launch the product in the fourth quarter 2004. Watson currently markets the product in the United States under the name OXYTROL®.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers